Login or Join
 Learn then Earn
stockMarketNEWS

 story : Regeneron says its COVID-19 antibody therapy cut risk of infection progression #FinanceUSA #StockMarketNEWS Shares of Regeneron Pharmaceuticals Inc. gained 1.6% in premarket trading on Monday after

@stockMarketNEWS Tue 13 Apr, 2021

Posted in: #FinanceUSA #StockMarketNEWS

Regeneron says its COVID-19 antibody therapy cut risk of infection progression #FinanceUSA #StockMarketNEWS
Shares of Regeneron Pharmaceuticals Inc. gained 1.6% in premarket trading on Monday after the company shared additional positive clinical data from two studies about its COVID-19 monoclonal antibody cocktail. One late-stage trial found that subcutaneous administration of REGEN-COV in recently infected asymptomatic patients lessened the overall risk to progressing to symptomatic infection by 31%. "These data pave the way for REGEN-COV to be used before patients become symptomatic, with a more convenient subcutaneous administration," Dr. Katharine Bar, one of the study's investigators, said in a news release. The treatment, REGEN-COV, is currently authorized only as an intravenous therapy. A second study found that subcutaneous administration of the antibody cocktail reduced the risk of symptomatic infections by 81% in people who shared a household with someone who had recently tested positive for the virus. Regeneron's stock is down 1.6% since the start of the year, while the broader S&P 500 is up 9.9%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme